Serum peroxisome proliferator-activated receptor-gamma levels in acute phase of male patients with schizophrenia and their relationship with metabolic parameters — Tevfik Kalelioğlu (2017) | RDL Network
Serum peroxisome proliferator-activated receptor-gamma levels in acute phase of male patients with schizophrenia and their relationship with metabolic parameters
Article 2017 en
Authors
TK
Tevfik Kalelioğlu
ND
Nurdan Durak
NK
Nesrin Karamustafalıoğlu
Abstract
1 min read
Objective: Peroxisome proliferator-activated receptors (PPARs) are a group of nuclear receptor family providing the modulation of the genes having a role in gluco-lipid metabolism and inflammation. Here, we aimed to compare serum PPARγ levels between medication-free schizophrenia patients and healthy controls.Methods: Forty-five inpatients with schizophrenia and 39 healthy controls were included in the study. Serum PPARγ levels and metabolic syndrome (MetS) parameters of the patients and controls were compared.Results: There were no statistically significant differences between the patients (1.42 ± 0.64 ng/ml) and the control group (1.59 ± 1.10 ng/ml) in terms of serum PPARγ levels. No statistically significant correlations were determined between the MetS parameters and PPARγ levels.Conclusions: Our findings showed that PPARγ, which we predicted to have a role in metabolic disorders and inflammatory process in schizophrenia, did not seem to have a role in the acute exacerbation of schizophrenia.
Discussion(0)
No comments yet. Be the first to comment.